GlassScriptPhysician profile
Michael Nmi Ramos
NPI 1063407781
$1,244.45
in general payments reported to CMS, 2019-2025
21 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $153 · 2021: $159 · 2022: $176 · 2023: $75.39 · 2024: $260 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $516.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.67 | 2021-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $203.26 | 2019-2024 | Vaxneuvance, Vaxelis, Capvaxive |
| Teva Pharmaceuticals USA, INC. | $114.93 | 2024-2025 | Austedo Xr, Austedo Xr |
| Pfizer INC. | $87.11 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $72.53 | 2022-2024 | Keveyis |
| Abbvie INC. | $64.81 | 2022-2024 | |
| Stimwave Technologies Incorporated | $64.07 | 2020 | |
| Aimmune Therapeutics, INC. | $58.23 | 2024-2025 | Zenpep, Vowst |
| Abbott Laboratories | $55.32 | 2021-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $53.38 | 2022-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $43.78 | 2025 | Mounjaro |
| Glaxosmithkline, LLC. | $31.97 | 2022-2024 | Trelegy Ellipta |
| Exact Sciences Corporation | $29.15 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Genentech USA, INC. | $27.51 | 2019 | |
| Grifols USA, LLC | $21.16 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $20.93 | 2025 | Neffy |
| Allergan, INC. | $20.86 | 2020 | |
| Paratek Pharmaceuticals, INC. | $18.22 | 2024 | Nuzyra |
| Amgen INC. | $16.31 | 2019 | |
| Antares Pharma, INC. | $16.13 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $15.12 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.